The risk of locoregional recurrence varies considerably by molecular subtype, with luminal A and B cancers showing very low recurrence rates, whereas TNBC and HER2-positive cancers demonstrate a considerably higher risk [24,25,26,27,28]. Here, ERBB2 is linked to cancer.